Premium
Estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic stem cell transplantation by the amount of BCR‐ABL fusion transcripts detected using a new real‐time polymerase chain reaction method
Author(s) -
Elmaagacli Ahmet H.,
Freist Annette,
Hahn Meinhard,
Opalka Bertram,
Seeber Siegfried,
Schaefer Ulrich W.,
Beelen D. W.
Publication year - 2001
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2001.02858.x
Subject(s) - housekeeping gene , transplantation , real time polymerase chain reaction , breakpoint cluster region , fusion gene , serial dilution , stem cell , taqman , chronic myeloid leukaemia , polymerase chain reaction , abl , minimal residual disease , medicine , immunology , fusion transcript , myeloid , biology , reverse transcriptase , reverse transcription polymerase chain reaction , leukemia , gene expression , gene , pathology , receptor , tyrosine kinase , genetics , alternative medicine
We have used a new single‐step real‐time reverse transcription polymerase chain reaction (RT‐PCR) method to quantify BCR‐ABL transcripts, thereby estimating the relapse stage in chronic myeloid leukaemia patients after allogeneic transplants. In 402 samples from 172 patients, BCR‐ABL expression was determined and normalized, using the GAPDH housekeeping gene product as an endogenous reference. In our real‐time RT‐PCR assay, serial dilutions of RNA of the K562 cell line remained positive down to 7·5 pg. The median normalized BCR‐ABL amount differed significantly ( P < 0·001) between the various disease stages and was 0·06% (range 0·001–1·55%), 3·2% (range 1·4–5·6%) and 21·5% (range 6·8 −827%) in 17 patients with a molecular relapse, in eight patients with a cytogenetic relapse and in 10 patients with a haematological relapse respectively.